QuidelOrtho Corp (QDEL)

22.13 -0.47 (-2.08%)

As of 2026-03-02 18:39:56 EST

QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration (FDA) issued to Quidel the first emergency use authorization (EUA) for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.

Traded asNasdaq: QDEL
ISINUS2197981051
CIK0001906324
LEI549300YU8CMO9HF53113
EIN874496285
Sector—
IndustryIn Vitro & In Vivo Diagnostic Substances
CEOBrian Blaser
Employees7,100
Fiscal Year End0101
Address9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA, 92121
Phone(858) 552-1100
Websitehttp://quidelortho.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
QDELQuidelOrtho Corp2026-03-02 18:39:5622.13-0.47-2.08
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
QDEL0001906324QuidelOrtho CorpUS2197981051549300YU8CMO9HF53113874496285Nasdaq2835In Vitro & In Vivo Diagnostic Substances0101—9975 SUMMERS RIDGE ROADSAN DIEGOCA92121UNITED STATESUS(858) 552-11009975 SUMMERS RIDGE ROAD, SAN DIEGO, CA, 921219975 SUMMERS RIDGE ROAD, SAN DIEGO, CA, 92121Coronado Topco, Inc.—1979Brian Blaser7,100http://quidelortho.com1,940,523,40867,900,00068,081,767QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration (FDA) issued to Quidel the first emergency use authorization (EUA) for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.2026-02-26 17:43:20
This is a preview of the latest data. Subscribe to access the full data.
QDEL Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
QDEL Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20251,940,523,408-242,095,869-11.09268,081,767635,2230.9418
20242,182,619,277-2,906,952,565-57.115967,446,544597,0540.8931
20235,089,571,842-918,630,753-15.289666,849,490343,9440.5172
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Robert J. BujarskiEVP, President, COO2024575,76302,999,91702,862,7976,438,477
Michael S. IskraCEO, EVP2024575,76302,999,91702,615,8936,191,573
Brian J. BlaserCEO, President2024634,615013,434,938863,014112,37015,044,937
Douglas C. BryantCEO, President2024176,67706,199,87934,6135,638,89612,050,065
Patrick E. KleinSVP2024136,7500642,92301,407,1112,543,141
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20256,500
20246,600
20237,000
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue2,730,200,0002,782,900,0002,997,800,000
Cost Of Revenue1,456,000,0001,496,400,0001,503,400,000
Gross Profit30,900,00029,500,000—
Research And Development Expenses186,200,000218,700,000246,800,000
General And Administrative Expenses746,300,000766,800,000763,200,000
Operating Expenses134,300,000125,400,000124,100,000
Operating Income-919,200,000-1,960,900,000139,100,000
Net Income-1,131,800,000-2,052,000,000-10,100,000
Earnings Per Share Basic-16.69-30.54-0.15
Earnings Per Share Diluted-16.69-30.54-0.15
Weighted Average Shares Outstanding Basic67,800,00067,200,00066,800,000
Weighted Average Shares Outstanding Diluted67,800,00067,200,00066,800,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents169,800,00098,300,000118,900,000
Marketable Securities Current—048,400,000
Accounts Receivable417,000,000282,400,000303,300,000
Inventories577,600,000533,700,000577,800,000
Non Trade Receivables——104,700,000
Other Assets Current28,200,0001,100,0003,100,000
Total Assets Current1,447,300,0001,218,900,0001,310,500,000
Marketable Securities Non Current—07,400,000
Property Plant And Equipment——1,443,800,000
Other Assets Non Current244,400,000270,700,000179,600,000
Total Assets Non Current4,322,000,0005,204,700,0001,443,800,000
Total Assets5,769,300,0006,423,600,0008,563,100,000
Accounts Payable279,400,000246,000,000294,800,000
Deferred Revenue37,800,00033,500,00036,800,000
Short Term Debt178,300,000341,800,000139,800,000
Other Liabilities Current376,600,000288,700,000303,300,000
Total Liabilities Current966,100,000998,800,000833,800,000
Long Term Debt2,697,700,0002,488,600,0002,422,600,000
Other Liabilities Non Current166,400,00055,300,00083,600,000
Total Liabilities Non Current2,882,700,0002,440,300,0002,723,400,000
Total Liabilities3,848,800,0003,439,100,0003,557,200,000
Common Stock100,000100,000100,000
Retained Earnings-996,000,000135,800,0002,187,800,000
Accumulated Other Comprehensive Income-15,400,000-36,200,000-30,000,000
Total Shareholders Equity1,920,500,0002,984,500,0005,005,900,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization252,800,000250,000,000252,400,000
Share Based Compensation Expense45,900,00042,100,00051,600,000
Other Non Cash Income Expense—-1,200,000—
Change In Accounts Receivable117,500,000-5,400,000-160,000,000
Change In Inventories148,300,000134,100,000211,600,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable40,000,000-23,400,0003,000,000
Change In Other Liabilities92,000,000-22,600,000-5,900,000
Cash From Operating Activities105,200,00083,000,000280,200,000
Purchases Of Marketable Securities07,200,00060,100,000
Sales Of Marketable Securities063,100,00078,300,000
Acquisition Of Property Plant And Equipment188,200,000195,100,000209,300,000
Acquisition Of Business—00
Other Investing Activities11,000,00020,000,00010,000,000
Cash From Investing Activities-192,700,000-149,900,000-187,600,000
Tax Withholding For Share Based Compensation5,400,0009,600,00013,500,000
Payments Of Dividends———
Issuance Of Common Stock6,100,0005,000,00011,600,000
Repurchase Of Common Stock007,200,000
Issuance Of Long Term Debt———
Repayment Of Long Term Debt2,289,200,000——
Other Financing Activities———
Cash From Financing Activities155,800,00048,800,000-265,800,000
Change In Cash71,300,000-21,000,000-174,400,000
Cash At End Of Period169,800,00098,300,000118,900,000
Income Taxes Paid-25,400,00041,600,00086,600,000
Interest Paid172,400,000177,500,000150,000,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-16.69-30.54-0.15
Price To Earnings Ratio-1.7555-1.4407-491.3333
Earnings Growth Rate-45.350420,260-101.5528
Price Earnings To Growth Ratio0.0387-0.00014.8382
Book Value Per Share28.32644.412274.9386
Price To Book Ratio1.03440.99070.9835
Ebitda-726,800,000-1,923,900,000181,300,000
Enterprise Value4,692,740,0005,688,900,0007,366,660,000
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio1.49750.94840.5119
Capital Expenditures——357,200,000
Free Cash Flow——-77,000,000
Return On Equity-0.5893-0.6876-0.002
One Year Beta1.61910.52861.0431
Three Year Beta1.22880.9070.737
Five Year Beta0.92890.58110.6458
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Blaser Brian J.President and CEO2026-02-1310,540A40,073
Strobeck MatthewDirector2026-02-1310,000A27,775
Busky Joseph M.Chief Financial Officer2026-02-133,370A10,290
Hodges Michelle AChief Legal Officer2026-01-311,610A38,970
Hodges Michelle AChief Legal Officer2026-01-31578D38,392
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Daniel Goldman2023-08-13NY10Sale2023-07-12—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Compass Financial Services Inc2025-12-311,5715528.5636
Bell Investment Advisors, Inc2025-12-314861728.5882
MV CAPITAL MANAGEMENT, INC.2025-12-312,0857328.5616
Sunbelt Securities, Inc.2025-12-313431228.5833
T. Rowe Price Investment Management, Inc.2025-12-31337,925,00011,832,09828.56
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
PIMCO Equity Series2025-12-31Class APMJAX541,28315,459,042.480.5143
PIMCO Equity Series2025-12-31I-2PMJPX541,28315,459,042.480.5143
PIMCO Equity Series2025-12-31Institutional ClassPMJIX541,28315,459,042.480.5143
RYDEX SERIES FUNDS2025-12-31Class CRYCMX942,684.640.0318
RYDEX SERIES FUNDS2025-12-31Class ARYAKX942,684.640.0318
This is a preview of the latest data. Subscribe to access the full data.